Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Trulieve Cannabis (TCNNF) EBITDA (2020 - 2026)

Trulieve Cannabis has reported EBITDA over the past 6 years, most recently at $15.3 million for Q4 2025.

  • For Q4 2025, EBITDA rose 1069.5% year-over-year to $15.3 million; the TTM value through Dec 2025 reached $143.5 million, up 46.75%, while the annual FY2025 figure was $196.6 million, 63.7% up from the prior year.
  • EBITDA for Q4 2025 was $15.3 million at Trulieve Cannabis, down from $42.2 million in the prior quarter.
  • Over five years, EBITDA peaked at $83.6 million in Q2 2021 and troughed at -$291.3 million in Q2 2023.
  • A 5-year average of $16.2 million and a median of $39.8 million in 2023 define the central range for EBITDA.
  • Biggest five-year swings in EBITDA: crashed 573.07% in 2023 and later surged 6734.63% in 2025.
  • Year by year, EBITDA stood at -$12.2 million in 2021, then crashed by 65.89% to -$20.2 million in 2022, then surged by 66.14% to -$6.8 million in 2023, then soared by 119.15% to $1.3 million in 2024, then surged by 1069.5% to $15.3 million in 2025.
  • Business Quant data shows EBITDA for TCNNF at $15.3 million in Q4 2025, $42.2 million in Q3 2025, and $52.6 million in Q2 2025.